Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
O60282

UPID:
KIF5C_HUMAN

ALTERNATIVE NAMES:
Kinesin heavy chain neuron-specific 2; Kinesin-1

ALTERNATIVE UPACC:
O60282; O95079; Q2YDC5

BACKGROUND:
The protein Kinesin heavy chain isoform 5C, known alternatively as Kinesin heavy chain neuron-specific 2 or Kinesin-1, plays a significant role in organelle transport within neurons. It has ATPase activity and is involved in synaptic transmission, dendritic trafficking of mRNAs, and is crucial for the anterograde axonal transport of MAPK8IP3/JIP3, which is vital for axon elongation.

THERAPEUTIC SIGNIFICANCE:
Involvement of Kinesin heavy chain isoform 5C in Cortical dysplasia, complex, with other brain malformations 2, underscores its potential as a target for therapeutic intervention. This protein's critical role in neuronal development and function suggests that deeper understanding could lead to innovative treatments for related neurological disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.